医生对新诊断晚期卵巢癌患者遗传生物标志物检测的知识、使用和认知：国际医生调查
基于390名国际妇科/肿瘤医生的在线调查，评估晚期卵巢癌BRCAm和HRD遗传检测的知识、使用、障碍与认知。
基本信息
资源简介
医生对新诊断晚期卵巢癌患者遗传生物标志物检测的知识、使用和认知：国际医生调查
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 8 个文件、合计 577.31 KB，主题涵盖 Biomarker testing、BRCA mutation testing、homologous recombination deficiency、HRD genomic instability testing、olaparib，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey》。配套论文《Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey》发表于 Future Oncology（2025），DOI：10.1080/14796694.2025.2449782。项目资助方：This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA.。源站首次发布：2025-02-07。
【数据内容】
源站原始描述：To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management. Gynecology/oncology specialists (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey spanning March 2021 to April 2022. Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic ins…
中文译文（机器翻译，仅供快速理解，请以原文为准）：探讨医生对晚期卵巢癌管理中基因检测的知识、使用情况和认知。 美国、欧洲、加拿大、日本和澳大利亚的妇科/肿瘤专科医生（n=390）在2021年3月至2022年4月期间完成了一项在线调查。 医生报告的乳腺癌基因突变（BRCAm）检测率在调查前2年内有所增加；大多数患者在过去6个月内接受了检测。同源重组缺陷（HRD）基因组不稳定性检测率及医生解读结果的信心仍相对较低。基因检测的驱动力是检测结果对治疗的相关影响。体能状态差、组织不足以及患者接受检测的意愿被报告为检测障碍。 研究结果表明，需要改善HRD检测的可及性和相关信息。 我们为什么开展这项研究？ 强烈建议通过乳腺癌基因突变（BRCAm）检测来指导卵巢癌（OC）患者的治疗决策，同时也建议筛查同源重组缺陷（HRD）基因组不稳定性（即细胞无法准确修复DNA链断裂）。然而，并非所有符合条件的女性都接受了检测，这表明需要更深入地了解医生的检测实践。 我们做了什么？ 美国、欧洲、加拿大、日本和澳大利亚的医生（n=390）完成了一项在线调查，评估其对晚期OC管理中基因检测的知识、使用情况和认知。 结果如何？ 在所有国家中，医生报告在调查前2年内BRCAm检测率不断上升，目前大多数晚期OC患者正在接受这些检测。HRD检测率相对较低，且很少有医生报告对解读这些检测结果完全有信心。医生最常报告称，进行基因检测是因为结果可以指导治疗决策。不进行检测的主要原因包括患者病情过重、组织样本不足或患者不愿意接受检测。在各个国家中，大多数医生同意应向OC患者提供遗传咨询；然而，在一些国家，这些服务的可及性不足。 这些发现的意义是什么？ 我们的研究结果表明，医生对基因检测（包括HRD检测）更广泛影响的理解，以及患者获得遗传咨询的机会，可能需要改善，以确保晚期OC患者获得最佳治疗。
【数据结构与技术规格】
文件数 8 个，合计 577.31 KB。ifon_a_2449782_sm9877.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，18.87 KB。ifon_a_2449782_sm9876.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，17.88 KB。ifon_a_2449782_sm9872.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，24.54 KB。数据集 DOI：10.6084/m9.figshare.28218057.v2。
【主题与分类】
源站学科分类：Medicine、Genetics、Science Policy。主题标签：Biomarker testing、BRCA mutation testing、homologous recombination deficiency、HRD genomic instability testing、olaparib、ovarian cancer、PARP inhibitors、physician survey。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Physician_knowledge_use_and_perceptions_of_genetic_biomarker_testing_for_the_management_of_patients_with_newly_diagnosed_advanced_ovarian_cancer_an_international_physician_survey/28218057
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey. Taylor & Francis. Banerjee, Susana; Eskander, Ramez N.; Bailey, Tom; Ambler, Will; Volpe, Stephanie; Özgören, Ozan; e…
【使用注意】
· 源站最后修改于 2025-03-04，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey
- DOI：10.6084/m9.figshare.28218057.v2
- 发布日期：2025-02-07
- 文件数：8 个
- 文件总体积：577.31 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Physician_knowledge_use_and_perceptions_of_genetic_biomarker_testing_for_the_management_of_patients_with_newly_diagnosed_advanced_ovarian_cancer_an_international_physician_survey/28218057
命令行下载
curl -L -o "ifon_a_2449782_sm9877.docx" "https://ndownloader.figshare.com/files/52190154"
curl -L -o "ifon_a_2449782_sm9876.docx" "https://ndownloader.figshare.com/files/52190157"
curl -L -o "ifon_a_2449782_sm9872.docx" "https://ndownloader.figshare.com/files/52190160"
curl -L -o "ifon_a_2449782_sm9871.docx" "https://ndownloader.figshare.com/files/52190163"
curl -L -o "ifon_a_2449782_sm9870.docx" "https://ndownloader.figshare.com/files/52190166"
curl -L -o "ifon_a_2449782_sm9869.docx" "https://ndownloader.figshare.com/files/52190169"
curl -L -o "ifon_a_2449782_sm9866.pdf" "https://ndownloader.figshare.com/files/52190172"
curl -L -o "ifon_a_2449782_sm9858.docx" "https://ndownloader.figshare.com/files/52190175"
文件清单
ifon_a_2449782_sm9877.docx（18.87 KB）ifon_a_2449782_sm9876.docx（17.88 KB）ifon_a_2449782_sm9872.docx（24.54 KB）ifon_a_2449782_sm9871.docx（32.73 KB）ifon_a_2449782_sm9870.docx（18.88 KB）ifon_a_2449782_sm9869.docx（17.07 KB）ifon_a_2449782_sm9866.pdf（427.81 KB）ifon_a_2449782_sm9858.docx（19.52 KB）
文件总体积 577.31 KB（源站 API 实测）。
数据说明
To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management.
Gynecology/oncology specialists (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey spanning March 2021 to April 2022.
Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic instability testing rates and physicians’ confidence interpreting results remained relatively low. Genetic testing was driven by the associated treatment implications of the findings. Poor performance status, inadequate tissue, and patients’ willingness to undergo testing were reported barriers to testing.
Findings indicate that there is a need to improve both access to and information about HRD testing.
Why did we perform this research?
Testing for breast cancer gene mutations (BRCAm) is strongly recommended to guide treatment decisions for patients with ovarian cancer (OC), with screening for homologous recombination deficiency (HRD) genomic instability (when cells cannot accurately repair breaks in DNA strands) also recommended. However, not all eligible women are tested, indicating that a greater understanding of physicians’ testing practices is needed.
What did we do?
Physicians (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey that evaluated their knowledge, use, and perceptions of genetic testing for advanced OC management.
What were the results?
Across all countries, physicians reported increasing BRCAm testing rates over the 2 years before the survey, with most patients with advanced OC now receiving these tests. HRD testing rates were relatively low, and few physicians reported complete confidence in interpreting these test results. Physicians most commonly reported that genetic testing was conducted because the results could guide treatment decisions. The main reasons for not conducting tests were patients being too unwell, tissue samples being inadequate, or patients being unwilling to undergo testing. Across countries,
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.28218057.v2（source: https://tandf.figshare.com/articles/dataset/Physician_knowledge_use_and_perceptions_of_genetic_biomarker_testing_for_the_management_of_patients_with_newly_diagnosed_advanced_ovarian_cancer_an_international_physician_survey/28218057）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
